In July 2015 the Secretary of State for Health, Jeremy Hunt, delivered a speech ‘Making healthcare more human-centred and not system-centred’ (link provided below). In this speech, he outlined his commitment to seven-day care and highlighted variation in outcomes associated with weekend hospitalisation.
The experimental statistics presented in this report are being published to provide a starting point for discussions on how we can effectively measure both improvement and variation in care provision across the week.
Statistics about emergency readmissions by day of discharge and length of stay in hospital for emergency admissions by day of admission are included in this initial publication. Statistics examining mortality by day of admission are planned for future releases of this series.
Patient benefits include: 100 per cent appointment attendance rates, minimal delays, reduced A&E care, less use of mental health services, reduction of fear and stigma, accessibility, choice, specialist tests close to home, only giving information once and having clear agreed care plans.
The Nuffield Trust has published What do leaders want from NHS Improvement? This publication is the latest in the Nuffield Trust’s Viewpoint series, which provides a platform for different and diverse views on change and reform in the NHS. In this publication The Nuffield Trust and NHS Providers asked leaders from across the health service and other key positions in health care policy for their advice to the first leader of the powerful new regulator of health service providers, NHS Improvement.
People who have high blood pressure are almost 60% more likely to develop diabetes, according to research on 4.1 million people.
Background Reliable quantification of the association between blood pressure (BP) and risk of type 2 diabetes is lacking.
Objectives This study sought to determine the association between usual BP and risk of diabetes, overall and by participant characteristics.
Methods A cohort of 4.1 million adults, free of diabetes and cardiovascular disease, was identified using validated linked electronic health records. Analyses were complemented by a meta-analysis of prospective studies that reported relative risks of new-onset diabetes per unit of systolic blood pressure (SBP).
Results Among the overall cohort, 20 mm Hg higher SBP and 10 mm Hg higher diastolic BP were associated with a 58% and a 52% higher risk of new-onset diabetes (hazard ratio: 1.58; 95% confidence interval [CI]: 1.56 to 1.59; and hazard ratio: 1.52; 95% confidence interval: 1.51 to 1.54), respectively. There was no evidence of a nadir to a baseline BP of 110/70 mm Hg. The strength of the association per 20 mm Hg higher SBP declined with age and with increasing body mass index. Estimates were similar even after excluding individuals prescribed antihypertensive or lipid-lowering therapies. Systematic review identified 30 studies with 285,664 participants and 17,388 incident diabetes events. The pooled relative risk of diabetes for a 20 mm Hg higher usual SBP across these studies was 1.77 (1.53 to 2.05).
Conclusions People with elevated BP are at increased risk of diabetes. The strength of the association declined with increasing body mass index and age. Further research should determine if the observed risk is modifiable.
The Oxford University study provides the strongest evidence yet of a link between the two conditions.
Experts behind the study said more research was needed to see whether using drugs to lower blood pressure would help prevent people developing type 2 diabetes.
Prof Kazem Rahimi, deputy director of the George Institute for Global Health UK at Oxford, which carried out the study, said: “This is potentially a game changer in the understanding and treatment of diabetes.
In this webinar, Dr Brian Robson and Professor Tony Cornford explore how technology can improve health care, the challenges of digital innovation and the potential for it to lead to long-term improvements in patient care.
A daily dose of aspirin can double the life expectancy of patients with cancers affecting the gastrointestinal tract, according to a study. It was already known that that frequent use of aspirin can prevent bowel cancer, but the most recent study also suggests that men and women with a range of cancers who take the anti-inflammatory painkiller experience a significant survival benefit compared with those who do not. The study of 14,000 cancer patients in the Netherlands found that regular users of aspirin were twice as likely to still be alive after a four-year period as those who did not take the cheap drug. According to the report’s authors…